
|Videos|April 14, 2023
Should Men with Prior CVD be Treated Preferentially with a GnRH Antagonist?
Dr Higano provides a timeline review of safety results for GnH agonists and GnRH antagonists including the recent prospective phase 3 PRONOUNCE study for prostate cancer patients with pre-existing CV disease, followed by closing thoughts on this video series.
Advertisement
January 2023 AbbVie Inc. Company Confidential
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Ravi Munver, MD, highlights study of first- and second-generation Aquablation systems
2
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
3
EV plus pembro approval reframes first conversation in MIBC diagnosis
4
Genomic Prostate Score may help refine risk assessment in localized prostate cancer
5














